|1.||Tay, Yong-Kwang: 1 article (11/2006)|
|2.||Ng, Victor: 1 article (11/2006)|
|3.||Oh, Daniel C T: 1 article (11/2006)|
|4.||Teo, Rachael Y L: 1 article (11/2006)|
|5.||Tan, Chong-Hiok: 1 article (11/2006)|
|6.||Oh, H M L: 1 article (05/2004)|
|7.||Tee, A K H: 1 article (05/2004)|
|8.||Wee, I Y J: 1 article (05/2004)|
|9.||Poh, W T: 1 article (05/2004)|
|10.||Khoo, B P: 1 article (05/2004)|
11/01/2006 - "As maloprim is widely used for malaria prophylaxis, clinicians need to be aware of this unusual but potentially serious association."
01/01/1997 - "Maloprim malaria prophylaxis in children living in a holoendemic village in north-eastern Tanzania."
11/01/1995 - "The incidence of clinical attacks of malaria during the year after medication was stopped was significantly higher among children who had previously received Maloprim for several years than among children who had previously received placebo. "
06/01/1993 - "In The Gambia, insecticide impregnation of bed nets, used alone or combined with Maloprim, reduced morbidity and mortality from malaria amongst children between one and 4 years of age. "
11/01/1989 - "During a one-year period after termination of prophylaxis, there was no increase in the frequency of clinical episodes of malaria in the children who had received Maloprim. "
04/05/1993 - "To assess the value of various drug regimens for malaria prophylaxis under circumstances where dapsone and pyrimethamine (combined as Maloprim) and chloroquine, followed by the 14-day primaquine eradication course, were no longer effective in protecting military personnel against falciparum and vivax malaria. "
|3.||Leprosy (Hansen's Disease)
03/01/1997 - "Hyperpigmented lesions similar to those reported in this study have been described previously in patients with leprosy treated with dapsone, and the dapsone component of Maloprim is the likely cause of the skin reactions seen in children given this drug for malaria chemoprophylaxis."
04/12/2001 - "The incidence of agranulocytosis in subjects taking oral dapsone in combination with maloprim for malaria is 1 -- 10-20,000 while leprosy patients treated with dapsone exhibit virtually zero risk of agranulocytosis. "
07/01/1986 - "Twenty-one cases of agranulocytosis following dosage with one tablet of Maloprim given once or twice weekly are reviewed. "
07/01/1986 - "Agranulocytosis associated with maloprim: review of cases."
01/07/1984 - "Agranulocytosis associated with Maloprim."
12/24/1983 - "Maloprim and agranulocytosis."
05/07/1983 - "Agranulocytosis associated with Maloprim."
|5.||Falciparum Malaria (Plasmodium falciparum Malaria)
12/11/1982 - "Inadequate prophylaxis of Plasmodium falciparum malaria with once-a-week Maloprim therapy."
10/01/1983 - "Treatment of falciparum malaria with a single dose combination of dapsone and pyrimethamine (Maloprim)."
03/18/1985 - "The dapsone-pyrimethamine combination (100 mg of dapsone, 12.5 mg of pyrimethamine [Folaprim; Maloprim, one tablet a week) is considered to provide adequate prophylaxis for Plasmodium falciparum malaria, but to be inadequate for the prevention of P. "
|7.||Folic Acid (Vitamin M)